Publications

Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Conde, J., J. M. de la Fuente, and P. V. Baptista. "In vitro transcription and translation inhibition via DNA functionalized gold-nanoparticles." Nanotechnology 21 (2010): 505101.
Conde, João, Jesús M. de la Fuente, and Pedro V. Baptista. "RNA quantification using gold nanoprobes - application to cancer diagnostics." J. Nanobiotechnology 8 (2010): 5.
Conde, João, Miguel Larguinho, Ana Cordeiro, Luis R. Raposo, Pedro M. Costa, Susana Santos, Mário Diniz, Alexandra R. Fernandes, and Pedro Viana Baptista. "Gold-Nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis." Nanotoxicology 8 (2014): 521-532. AbstractWebsite

Antisense therapy is a powerful tool for post-transcriptional gene silencing suitable for down-regulating target genes associated to disease. Gold nanoparticles have been described as effective intracellular delivery vehicles for antisense oligonucleotides providing increased protection against nucleases and targeting capability via simple surface modification. We constructed an antisense gold-nanobeacon consisting of a stem-looped oligonucleotide double-labelled with 3′-Cy3 and 5′-Thiol-C6 and tested for the effective blocking of gene expression in colorectal cancer cells. Due to the beacon conformation, gene silencing was directly detected as fluorescence increases with hybridisation to target, which can be used to assess the level of silencing. Moreover, this system was extensively evaluated for the genotoxic, cytotoxic and proteomic effects of gold-nanobeacon exposure to cancer cells. The exposure was evaluated by two-dimensional protein electrophoresis followed by mass spectrometry to perform a proteomic profile and 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay, glutathione-S-transferase assay, micronucleus test and comet assay to assess the genotoxicity. This integrated toxicology evaluation showed that the proposed nanotheranostics strategy does not exhibit significant toxicity, which is extremely relevant when translating into in vivo systems.

Conde, Joao, Furong Tian, Yulan Hernandez, Chenchen Bao, Daxiang Cui, Klaus-Peter Janssen, M. Ricardo Ibarra, Pedro V. Baptista, Tobias Stoeger, and Jesus M. de la Fuente. "In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models." Biomaterials 34 (2013): 7744-7753. Abstract

n/a

Conde, Joao, Jorge T. Dias, Valeria Grazu, Maria Moros, Pedro V. Baptista, and Jesus M. de la Fuente. "Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine." Frontiers in Chemistry 2 (2014). Abstract

n/a

Conde, Joao, Alfredo Ambrosone, Vanesa Sanz, Yulan Hernandez, Valentina Marchesano, Furong Tian, Hannah Child, Catherine C. Berry, Ricardo M. Ibarra, Pedro V. Baptista, Claudia Tortiglione, and Jesus M. de la Fuente. "Design of Multifunctional Gold Nanoparticles for In Vitro and In Vivo Gene Silencing." Acs Nano 6 (2012): 8316-8324. Abstract

n/a

Conde, J., J. Rosa, J. C. Lima, and P. V. Baptista. "Nanophotonics for Molecular Diagnostics and Therapy Applications." International Journal of Photoenergy (2012). Abstract

n/a

Conde, João, Pedro V. Baptista, Yulan Hernández, Vanesa Sanz, and Jesus M. de la Fuente. "Modification of plasmid DNA topology by ‘histone-mimetic’ gold nanoparticles." Nanomedicine (2012).
Conde, João, Alfredo Ambrosone, Yulán Hernandez, Furong Tian, Mark McCully, Catherine C. Berry, Pedro V. Baptista, and Claudia T. " 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeutics." NANO TODAY In Press (2015). Abstract

RNAi has always captivated scientists due to its tremendous power to modulate the phenotype of living organisms. This natural and powerful biological mechanism can now be harnessed to down-regulate specific gene expression in diseased cells; opening up endless opportunities. Since most of the conventional siRNA delivery methods are limited by a narrow therapeutic index and significant side and off-target effects, we are now in the dawn of a new age in gene therapy driven by nanotechnology vehicles for RNAi therapeutics. Here, we outlook the "do's and dont's" of the inorganic RNAi nanomaterials developed in the last 15 years and the different strategies employed are compared and scrutinized, offering important suggestions for the next 15.

Conde, Joao, Goncalo Doria, and Pedro Baptista. "Noble metal nanoparticles applications in cancer." Journal of drug delivery 2012 (2012): 751075. Abstract

n/a

Conde, Joao, Chenchen Bao, Daxiang Cui, Pedro V. Baptista, and Furong Tian. "Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics." Journal of Controlled Release 183 (2014): 87-93. Abstract

n/a

Conde, João, Jesus M. de la Fuente, and Pedro V. Baptista. "Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?" Front. Pharmacol. (2013).
Conde, J., J. M. de la Fuente, and P. V. Baptista. "Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea?" Front Pharmacol 4 (2013): 134. AbstractWebsite

n/a

Cordeiro, Milton, Lara Carvalho, Joana Silva, Leonor Saúde, Alexandra R. Fernandes, and Pedro V. Baptista. "Gold nanobeacons for tracking gene silencing in Zebrafish." Nanomaterials (2017). AbstractWebsite

The use of gold nanoparticles for effective gene silencing has demonstrated its potential as a tool for gene expression experiments and for the treatment of several diseases. Here, we used a gold nanobeacon designed to specifically silence the enhanced green fluorescence protein (EGFP) mRNA in embryos of a fli-EGFP transgenic zebrafish line, while simultaneously allowing the tracking and localization of the silencing events via the beacon’s emission. Fluorescence imaging measurements demonstrated a decrease of the EGFP emission with a concomitant increase in the fluorescence of the Au-nanobeacon. Furthermore, microinjection of the Au-nanobeacon led to a negligible difference in mortality and malformations in comparison to the free oligonucleotide, indicating that this system is a biocompatible platform for the administration of gene silencing moieties. Together, these data illustrate the potential of Au-nanobeacons as tools for in vivo zebrafish gene modulation with low toxicity which may be used towards any gene of interest.

Cordeiro, Mílton, Ana Rita Otrelo-Cardoso, Dmitri I. Svergun, Petr V. Konarev, João Carlos Lima, Teresa Santos-Silva, and Pedro Viana Baptista. "Optical and Structural Characterization of a Chronic Myeloid Leukemia DNA Biosensor." ACS Chemical BiologyACS Chemical Biology 13 (2018): 1235-1242. AbstractWebsite

n/a

Cordeiro, Mílton, Fábio Ferreira Carlos, Pedro Pedrosa, António Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016): 43. AbstractWebsite

The remarkable physicochemical properties of gold nanoparticles (AuNPs) have prompted developments in the exploration of biomolecular interactions with AuNP-containing systems, in particular for biomedical applications in diagnostics. These systems show great promise in improving sensitivity, ease of operation and portability. Despite this endeavor, most platforms have yet to reach maturity and make their way into clinics or points of care (POC). Here, we present an overview of emerging and available molecular diagnostics using AuNPs for biomedical sensing that are currently being translated to the clinical setting.

Cordeiro, M., L. Giestas, J. C. Lima, and Pedro Viana Baptista. "Coupling an universal primer to SBE combined spectral codification strategy for single nucleotide polymorphism analysis." J Biotechnol 168 (2013): 90-94. AbstractWebsite

We previously reported a strategy that combines Förster resonance energy transfer (FRET) based spectral codification with a single base extension (SBE) reaction for single nucleotide sequence discrimination in solution. This strategy is capable of unequivocally detect the allele variants present in solution. To extend the use of this tool to any locus of interest, it would be required the development of an universal approach capable of combining a sequence specific SBE primer to an universal sequence labeled and optimized for spectral codification.
Here, we extend this concept to a general strategy by means of a labeled universal oligonucleotide primer (donor), a sequence specific primer that allows for incorporation of the complementary acceptor labeled ddNTP, which allows discrimination the allele variant in the sample via the unambiguous FRET signature of the donor/acceptor pair.

Cordeiro, Milton, Fabio Ferreira Carlos, Pedro Pedrosa, Antonio Lopez, and Pedro Viana Baptista. "Gold Nanoparticles for Diagnostics: Advances towards Points of Care." Diagnostics 6 (2016). Abstract

n/a

Cordeiro, Milton, Leticia Giestes, Joao Carlos Lima, and Pedro Baptista. "BioCode gold-nanobeacon for the detection of fusion transcripts causing chronic myeloid leukemia." Journal of Nanobiotechnology 38 (2016). AbstractWebsite

Background
Gold-nanobeacons (Au-nanobeacons) have proven to be versatile systems for molecular diagnostics and therapeutic actuators. Here, we present the development and characterization of two gold nanobeacons combined with Förster resonance energy transfer (FRET) based spectral codification for dual mode sequence discrimination. This is the combination of two powerful technologies onto a single nanosystem.

Results
We proved this concept to detect the most common fusion sequences associated with the development of chronic myeloid leukemia, e13a2 and e14a2. The detection is based on spectral shift of the donor signal to the acceptor, which allows for corroboration of the hybridization event. The Au-nanobeacon acts as scaffold for detection of the target in a homogenous format whose output capability (i.e. additional layer of information) is potentiated via the spectral codification strategy.

Conclusions
The spectral coded Au-nanobeacons permit the detection of each of the pathogenic fusion sequences, with high specificity towards partial complementary sequences. The proposed BioCode Au-nanobeacon concept provides for a nanoplatform for molecular recognition suitable for cancer diagnostics.

Corvo, Luísa M., Ana Soraia Mendo, Sara Figueiredo, Rogério Gaspar, Miguel Larguinho, Fátima Guedes M. C. da Silva, Pedro Viana Baptista, and Alexandra R. Fernandes. "Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy." Pharmaceutical Research (2016).
Costa, M. N., B. Veigas, J. M. Jacob, D. S. Santos, J. Gomes, P. V. Baptista, R. Martins, J. Inacio, and E. Fortunato. "A low cost, safe, disposable, rapid and self-sustainable paper-based platform for diagnostic testing: lab-on-paper." Nanotechnology 25 (2014). Abstract

n/a

Costa, P., A. Amaro, A. Botelho, J. Inacio, and P. V. Baptista. "Gold nanoprobe assay for the identification of mycobacteria of the Mycobacterium tuberculosis complex." Clinical Microbiology and Infection 16 (2010): 1464-1469. Abstract

n/a

Costa, Pedro, Ana Amaro, Ana Botelho, João Inácio, and Pedro V. Baptista. "Gold nanoprobes assay for identification of mycobacteria from the Mycobacterium tuberculosis complex." Clin Microbiol Infect. 16 (2010): 1464-1469.
Costa, P., A. Amaro, A. Botelho, J. Inácio, and P. V. Baptista. "Gold nanoprobe assay for the identification of mycobacteria of the Mycobacterium tuberculosis complex." Clin Microbiol Infect 16 (2010): 1464-9. AbstractWebsite

n/a